Interferon alfa-n1
Also known as: Human lymphoblastoid interferon, IFN-alfa-n1, IFN‑α N1, Interferon alfa‑n1, Interferon alpha N1, Lymphoblastoid interferon alfa, Wellferon
Source Interferon alfa-n1 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant interferon alfa‑n1 is a subtype of human interferon‑α used experimentally for antiviral (e.g., hepatitis B/C) and antitumor indications. It exerts antiviral effects by up‑regulating innate immune pathways and inhibiting viral replication.
Mechanism of Action
binds interferon‑α/β receptor (IFNAR) → JAK‑STAT signaling → induction of antiviral, antiproliferative and immunomodulatory genes
Routes of Administration
Goals & Uses
- Antiviral therapyInfectious DiseaseModerate
- Chronic Hepatitis C treatmentAntiviralHigh
- ImmunomodulationImmunologyModerate
- Cancer adjunctOncologyLow
- Antiviral activity (general)AntiviralModerate
- Antiproliferative / oncology supportOncologyModerate
Contraindications
- Severe psychiatric disorders (uncontrolled)PsychiatryHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to interferon alfa or any excipientAllergy/ImmunologyHigh
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Decompensated liver diseaseHepatic ImpairmentHigh
Adverse Effects
- Hematologic toxicity (neutropenia, thrombocytopenia, anemia)HematologicCommon
- LeukopeniaHematologicUncommonLow white blood cell count
- Depression and neuropsychiatric effectsNeuropsychiatricCommon
- Injection site reactionsLocalCommon
- AlopeciaDermatologicUncommonHair loss
- Flu‑like syndromeSystemicCommon
- Thyroid dysfunctionEndocrineUncommon
- Flu-like syndrome (fever, chills, myalgia, fatigue)SystemicCommon
- DepressionPsychiatricUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
Drug Interactions
- Myelosuppressive agentsHigh
- Live vaccinesHigh
- Immunosuppressants (e.g., cyclosporine)Moderate
- RibavirinModerate
- TheophyllineModerate
- MethadoneModerate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pediatric patients (<12 y)AgeRelative
- Pre-existing cardiac diseaseCardiovascularRelative
- Pregnant womenReproductiveAbsolute
- Elderly patients (≥65 years)Age RelatedRelative
- Elderly (>65 y)AgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA marketing authorization
- JPApprovedApproved: chronic hepatitis BLimited market approval under local brand
- United StatesInvestigationalNot FDA‑approved; IND status only
- United KingdomApprovedApproved: Chronic hepatitis CWellferon was approved by UK authorities for chronic hepatitis C; marketing status may be discontinued.
Not approved by FDA or EMA; limited clinical use in select Asian markets; primarily studied in phase I/II trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Interferon alfa-n1?
Recombinant interferon alfa‑n1 is a subtype of human interferon‑α used experimentally for antiviral (e.g., hepatitis B/C) and antitumor indications. It exerts antiviral effects by up‑regulating innate immune pathways and inhibiting viral replication.
What is Interferon alfa-n1 used for?
Interferon alfa-n1 is educationally associated with: Antiviral therapy, Chronic Hepatitis C treatment, Immunomodulation, Cancer adjunct, Antiviral activity (general), Antiproliferative / oncology support. Educational only — not medical advice.
How is Interferon alfa-n1 administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Interferon alfa-n1?
Reported adverse effects include: Hematologic toxicity (neutropenia, thrombocytopenia, anemia), Leukopenia, Depression and neuropsychiatric effects, Injection site reactions, Alopecia, Flu‑like syndrome, Thyroid dysfunction, Flu-like syndrome (fever, chills, myalgia, fatigue), Depression, Elevated liver enzymes. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interferon alfa-n1?
Recorded contraindications: Severe psychiatric disorders (uncontrolled), Severe hepatic impairment, Autoimmune disease, Pregnancy, Hypersensitivity to interferon alfa or any excipient, Autoimmune hepatitis, Decompensated liver disease. Consult a qualified clinician before use.